Adiponectin (also referred to as GBP-28, apM1, AdipoQ and Acrp30) is a protein hormone which is involved in regulating glucose levels as well as fatty acid breakdown. In humans it is encoded by the ADIPOQgene and it is produced in adipose tissue.
Adiponectin is a 247-amino-acid-long polypeptide (protein). There are four distinct regions of adiponectin. The first is a short signal sequence that targets the hormone for secretion outside the cell; next is a short region that varies between species; the third is a 65-amino acid region with similarity to collagenous proteins; the last is a globular domain. Overall this protein shows similarity to the complement 1Q factors (C1Q). However, when the 3-dimensional structure of the globular region was determined, a striking similarity to TNFα was observed, despite unrelated protein sequences.
Adiponectin is a protein hormone that modulates a number of metabolic processes, including glucose regulation and fatty acidoxidation. Adiponectin is secreted from adipose tissue (and also from the placenta in pregnancy) into the bloodstream and is very abundant in plasma relative to many hormones. Many studies have found adiponectin to be inversely correlated with body mass index in patient populations. However, a meta analysis was not able to confirm this association in healthy adults. Circulating adiponectin concentrations increase during caloric restriction in animals and humans, such as in patients with anorexia nervosa. This observation is surprising, given that adiponectin is produced by adipose tissue. However, a recent study suggests that adipose tissue within bone marrow, which increases during caloric restriction, contributes to elevated circulating adiponectin in this context.
Adiponectin is secreted into the bloodstream where it accounts for approximately 0.01% of all plasma protein at around 5-10 μg/mL (mg/L). In adults, plasma concentrations are higher in females than males, and are reduced in diabetics compared to non-diabetics. Weight reduction significantly increases circulating concentrations.
Adiponectin automatically self-associates into larger structures. Initially, three adiponectin molecules bind together to form a homotrimer. The trimers continue to self-associate and form hexamers or dodecamers. Like the plasma concentration, the relative levels of the higher-order structures are sexually dimorphic, where females have increased proportions of the high-molecular weight forms. Recent studies showed that the high-molecular weight form may be the most biologically active form regarding glucose homeostasis. High-molecular-weight adiponectin was further found to be associated with a lower risk of diabetes with similar magnitude of association as total adiponectin. However, coronary artery disease has been found to be positively associated with high molecular weight adiponectin, but not with low molecular weight adiponectin.
Adiponectin exerts some of its weight reduction effects via the brain. This is similar to the action of leptin; adiponectin and leptin can act synergistically.
These have distinct tissue specificities within the body and have different affinities to the various forms of adiponectin. The receptors affect the downstream target AMP kinase, an important cellular metabolic rate control point. Expression of the receptors is correlated with insulin levels, as well as reduced in mouse models of diabetes, particularly in skeletal muscle and adipose tissue.. In 2016, the University of Tokyo announced it was launching an investigation into anonymously made claims of fabricated and falsified data on the identification of AdipoR1 and AdipoR2.
Adiponectin was first characterised in 1995 in differentiating 3T3-L1 adipocytes (Scherer PE et al.). In 1996 it was characterised in mice as the mRNA transcript most highly expressed in adipocytes. In 2007, adiponectin was identified as a transcript highly expressed in preadipocytes (precursors of fat cells) differentiating into adipocytes.
The human homologue was identified as the most abundant transcript in adipose tissue. Contrary to expectations, despite being produced in adipose tissue, adiponectin was found to be decreased in obesity. This downregulation has not been fully explained. The gene was localised to chromosome 3q27, a region highlighted as affecting genetic susceptibility to type 2 diabetes and obesity. Supplementation by differing forms of adiponectin was able to improve insulin control, blood glucose and triglyceride levels in mouse models.
Extracts of sweet potatoes have been reported to increase levels of adiponectin and thereby improve glycemic control in humans. However, a systematic review concluded there is insufficient evidence to support the consumption of sweet potatoes to treat type 2 diabetes mellitus.
^ abMaeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K (April 1996). "cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1)". Biochemical and Biophysical Research Communications. 221 (2): 286–9. doi:10.1006/bbrc.1996.0587. PMID8619847.
^Shapiro L, Scherer PE (March 1998). "The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor". Current Biology. 8 (6): 335–8. doi:10.1016/S0960-9822(98)70133-2. PMID9512423.
^ abcdDíez JJ, Iglesias P (March 2003). "The role of the novel adipocyte-derived hormone adiponectin in human disease". European Journal of Endocrinology. 148 (3): 293–300. doi:10.1530/eje.0.1480293. PMID12611609.
^Chen J, Tan B, Karteris E, Zervou S, Digby J, Hillhouse EW, Vatish M, Randeva HS (June 2006). "Secretion of adiponectin by human placenta: differential modulation of adiponectin and its receptors by cytokines". Diabetologia. 49 (6): 1292–302. doi:10.1007/s00125-006-0194-7. PMID16570162.
^ abcUkkola O, Santaniemi M (November 2002). "Adiponectin: a link between excess adiposity and associated comorbidities?". Journal of Molecular Medicine. 80 (11): 696–702. doi:10.1007/s00109-002-0378-7. PMID12436346.
^Kuo SM, Halpern MM (December 2011). "Lack of association between body mass index and plasma adiponectin levels in healthy adults". International Journal of Obesity. 35 (12): 1487–94. doi:10.1038/ijo.2011.20. PMID21364526.
^ abBauche IB, El Mkadem SA, Pottier AM, Senou M, Many MC, Rezsohazy R, Penicaud L, Maeda N, Funahashi T, Brichard SM (April 2007). "Overexpression of adiponectin targeted to adipose tissue in transgenic mice: impaired adipocyte differentiation". Endocrinology. 148 (4): 1539–49. doi:10.1210/en.2006-0838. PMID17204560.
^ abRenaldi O, Pramono B, Sinorita H, Purnomo LB, Asdie RH, Asdie AH (January 2009). "Hypoadiponectinemia: a risk factor for metabolic syndrome". Acta Medica Indonesiana. 41 (1): 20–4. PMID19258676.
^Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T (August 2001). "The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity". Nature Medicine. 7 (8): 941–6. doi:10.1038/90984. PMID11479627.
^Coppola A, Marfella R, Coppola L, Tagliamonte E, Fontana D, Liguori E, Cirillo T, Cafiero M, Natale S, Astarita C (May 2009). "Effect of weight loss on coronary circulation and adiponectin levels in obese women". International Journal of Cardiology. 134 (3): 414–6. doi:10.1016/j.ijcard.2007.12.087. PMID18378021.
^Rizza S, Gigli F, Galli A, Micchelini B, Lauro D, Lauro R, Federici M (April 2010). "Adiponectin isoforms in elderly patients with or without coronary artery disease". Journal of the American Geriatrics Society. 58 (4): 702–6. doi:10.1111/j.1532-5415.2010.02773.x. PMID20398150.
^Fang X, Sweeney G (November 2006). "Mechanisms regulating energy metabolism by adiponectin in obesity and diabetes". Biochemical Society Transactions. 34 (Pt 5): 798–801. doi:10.1042/BST0340798. PMID17052201.
^Bonnard C, Durand A, Vidal H, Rieusset J (February 2008). "Changes in adiponectin, its receptors and AMPK activity in tissues of diet-induced diabetic mice". Diabetes & Metabolism. 34 (1): 52–61. doi:10.1016/j.diabet.2007.09.006. PMID18222103.
^Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF (November 1995). "A novel serum protein similar to C1q, produced exclusively in adipocytes". The Journal of Biological Chemistry. 270 (45): 26746–9. doi:10.1074/jbc.270.45.26746. PMID7592907.
^ abcdLara-Castro C, Fu Y, Chung BH, Garvey WT (June 2007). "Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease". Current Opinion in Lipidology. 18 (3): 263–70. doi:10.1097/MOL.0b013e32814a645f. PMID17495599.
^ abHara K, Yamauchi T, Kadowaki T (April 2005). "Adiponectin: an adipokine linking adipocytes and type 2 diabetes in humans". Current Diabetes Reports. 5 (2): 136–40. doi:10.1007/s11892-005-0041-0. PMID15794918.
^ abVasseur F, Meyre D, Froguel P (November 2006). "Adiponectin, type 2 diabetes and the metabolic syndrome: lessons from human genetic studies". Expert Reviews in Molecular Medicine. 8 (27): 1–12. doi:10.1017/S1462399406000147. PMID17112391.
^Grimshaw CE, Matthews DA, Varughese KI, Skinner M, Xuong NH, Bray T, Hoch J, Whiteley JM (August 1992). "Characterization and nucleotide binding properties of a mutant dihydropteridine reductase containing an aspartate 37-isoleucine replacement". The Journal of Biological Chemistry. 267 (22): 15334–9. PMID1639779.
^Yuan J, Liu W, Liu ZL, Li N (2006). "cDNA cloning, genomic structure, chromosomal mapping and expression analysis of ADIPOQ (adiponectin) in chicken". Cytogenetic and Genome Research. 112 (1–2): 148–51. doi:10.1159/000087527. PMID16276104.
^Nishio S, Gibert Y, Bernard L, Brunet F, Triqueneaux G, Laudet V (June 2008). "Adiponectin and adiponectin receptor genes are coexpressed during zebrafish embryogenesis and regulated by food deprivation". Developmental Dynamics. 237 (6): 1682–90. doi:10.1002/dvdy.21559. PMID18489000.
^Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, Yamaguchi M, Tanabe H, Kimura-Someya T, Shirouzu M, Ogata H, Tokuyama K, Ueki K, Nagano T, Tanaka A, Yokoyama S, Kadowaki T (November 2013). "A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity". Nature. 503 (7477): 493–9. doi:10.1038/nature12656. PMID24172895.
^Ludvik B, Hanefeld M, Pacini G (July 2008). "Improved metabolic control by Ipomoea batatas (Caiapo) is associated with increased adiponectin and decreased fibrinogen levels in type 2 diabetic subjects". Diabetes, Obesity & Metabolism. 10 (7): 586–92. doi:10.1111/j.1463-1326.2007.00752.x. PMID17645559.
^Spranger J, Verma S, Göhring I, Bobbert T, Seifert J, Sindler AL, Pfeiffer A, Hileman SM, Tschöp M, Banks WA (January 2006). "Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells". Diabetes. 55 (1): 141–7. doi:10.2337/diabetes.55.1.141. PMID16380487.
^Hoffstedt J, Arvidsson E, Sjölin E, Wåhlén K, Arner P (March 2004). "Adipose tissue adiponectin production and adiponectin serum concentration in human obesity and insulin resistance". The Journal of Clinical Endocrinology and Metabolism. 89 (3): 1391–6. doi:10.1210/jc.2003-031458. PMID15001639.